Determination of nitrotyrosine concentrations in plasma samples of diabetes mellitus patients by four different immunoassays leads to contradictive results and disqualifies the majority of the tests

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 4, 2009, Pages 483-488

  Safinowski, Michael ^a   Wilhelm, Birgit ^a   Reimer, Tanja ^a   Weise, Alexander ^a   Thomé, Nicole ^a   Hänel, Heike ^a   Forst, Thomas ^a   Pfützner, Andreas ^a,b  

^a Institute for Clinical Research and Development   (Germany)

^b IKFE   (Germany)

Author keywords

Atherosclerosis; Nitrotyrosine; Oxidative stress; Test evaluation

Indexed keywords

3 NITROTYROSINE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY ANALYSIS;

DIABETES MELLITUS; HUMANS; IMMUNOASSAY; TYROSINE;

EID: 63849175246     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.095     Document Type: Article

References (39)

1. Poldermann KH, Stehouwer CD, van Kamp GJ, Gooren LJ. Effects of insulin infusion on endothelium-derived vasoactive substances. Diabetologia 1996;39:1284-92.
2. Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 2000;101:676-81.
3. Giugliano D, Ceriello A. Oxidative stress and diabetic vascular complications. Diabetes Care 1996;19:257-67.
4. +-ATPase activity. Am J Physiol Cell Physiol 2002;282: C560-6.
5. Korshunov SS, Skulachev VO, Strakov AA. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Lett 1997;416: 15-8.
6. Brodsky SV, Gao S, Li H, Goligorsky MS. Hyperglycemic switch from mitochondrial nitric oxide to superoxide production in endothelial cells. Am J Physiol Heart Circ Physiol 2002;283:H2130-9.
7. Altomare E, Vendemiale G, Chicco D, Procacci V, Cirelli F. Increased lipid peroxidation in type 2 poorly controlled diabetic patients. Diabet Metab 1992;18:264-71.
8. Dandona P, Thusu K, Cook S, Snyder B, Makowski J, Armstrong D, et al. Oxidative damage to DNA in diabetes mellitus. Lancet 1996;47:444-5.
9. McRury SM, Gordon D, Wilson R, Bradley H, Gemmell CG, Paterson JR, et al. A comparison of different methods of assessing free radical activity in type 2 diabetes and peripheral vascular disease. Diabet Med 1993; 10:331-5.
10. Sundaram RK, Bhaskar A, Vijayalingam S, Viswanatthan M, Mohan R, Shanmugasundaram KR. Antioxidant status and lipid peroxidation in type II diabetes with and without complications. Clin Sci 1996;90:255-60.
11. Velazques E, Winocour PH, Kesteven P, Alberti KG, Laker MF. Relation of lipid peroxides to macrovascular disease in type 2 diabetes. Diabet Med 1991;8:752-8.
12. Du XL, Stockklauser-Färber K, Rösen P. Generation of reactive oxygen intermediates, activation of NFkB, and induction of apoptosis in human endothelial cells by glucose: role of nitric oxide synthase? Free Rad Biol Med 1999;27:752-63.
13. Tak PP, Firestein GS. NF-kB: a key role in inflammatory diseases. J Clin Invest 2001;107:7-11.
14. Forst T, Kunt T, Kazda C, Lobisch M, Pfützner A. Die Rolle der Proteinkinase C in der Entwicklung mikrovasculärer Komplikationen des Diabetes mellitus. Diabetes Stoffwech 2002;11:62-70.
15. Krolewski AS, Warram JH, Freire MB. Epidemiology of late diabetic complications. Endocrinol Metab Clin North Am 1996;25:217-42.
16. Olsen BS, Johannesen J, Sjolie AK, Borch-Johnsen K, Hougarrdss P, Thorsteinsson B, et al. Metabolic control and prevalence of microvascular complications in young Danish patients with type 1 diabetes mellitus. Diabet Med 1999;16:79-85.
17. Muggeo M. Accelerated complications in type 2 diabetes mellitus: the need for greater awareness and earlier detection. Diabet Med 1998;15(Suppl 4):60-2.
18. Yudkin JS, Denver AE, Mohamed-Ali V, Ramaiya KL, Nagi DK, Goubet S, et al. The relationship of concentrations of insulin and proinsulin-like molecules with coronary heart disease prevalence and incidence. A study of two ethnic groups. Diabetes Care 1997;20:1093-100.
19. Bavenholm P, Proudler A, Tornvall P, Godsland I, Landou C, De Faire U, et al. Insulin, intact and split proinsulin, and coronary artery disease in young men. Circulation 1995;92:1422-9.
20. Haffner SM, Bowsher RR, Mykkanen L, Hazuda HP, Mitchell BD, Valdez RA, et al. Proinsulin and specific insulin concentration in high- and low-risk populations for NIDDM. Diabetes 1994;43:1490-3.
21. Strutton DR, Stang PE, Erbey JR, Lydick E. Estimated coronary heart disease attributable to insulin resistance in populations with and without type 2 diabetes mellitus. Am J Manag Care 2001;7:765-73.
22. The Diabetic Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
23. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
24. Kannel WB, McGee DL. Diabetes and cardiovascular disease: The Framingham Study. J Am Med Assoc 1979; 241:2035-8.
25. Keaney JF Jr, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, et al, the Framingham Study Investigators. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003;23:434-9.
26. Aslan M, Ozben T. Reactive oxygen and nitrogen species in Alzheimer's disease. Curr Alzheimer Res 2004;1: 111-9.
27. Beal MF. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J Bioenerg Biomembr 2004;36:381-6.
28. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003; 302:819-22.
29. Beckmann JS. Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res Toxicol 1996;9:836-44.
30. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996;271:C1424-37.
31. Quint P, Reutzel R, Mikulski R, McKenna R, Silverman DN. Crystal structure of nitrated human manganese superoxide dismutase: mechanism of inactivation. Free Radic Biol Med 2006;40:453-8.
32. Schmidt P, Youhnovski N, Daiber A, Balan A, Arsic M, Bachschmid M, et al. Specific nitration at tyrosine 430 revealed by high resolution mass spectrometry as basis for redox regulation of bovine prostacyclin synthase. J Biol Chem 2003;278:12813-9.
33. Nie H, Wu JL, Zhang M, Xu J, Zou MH. Endothelial nitric oxide synthase-dependent tyrosine nitration of prostacyclin synthase in diabetes in vivo. Diabetes 2006;55: 3133-41.
34. Zou MH, Cohen R, Ullrich V. Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. Endothelium 2004;11:89-97.
35. Ceriello A, Mercuri F, Quagliaro L, Assaloni R, Motz E, Tonutti L, et al. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 2001;44:834-8.
36. Hoeldtke RD, Bryner KD, McNeill DR, Hobbs GR, Riggs JE, Warehime SS, et al. Nitrosative stress, uric acid, and peripheral nerve function in early type 1 diabetes. Diabetes 2002;51:2817-25.
37. Ceriello A, Quagliaro L, Piconi L, Assaloni R, Da Ros R, Maier A, et al. Effect of postprandial hypertriglyceridemia and hyperglycemia as circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 2004;53:701-10.
38. Mori Y, Itoh Y, Obata T, Tajima N. Effects of pioglitazone vs. glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes. Endocrine 2006; 29:143-8.
39. Kaur H, Halliwell B. Evidence for nitric-oxide mediated oxidative damage in chronic inflammation: nitrotyrosine in serum and synovial fluid from rheumatoid patients. FEBS Lett 1994;350:9-12.